NIH Award $11-Million Grant to Brown University for Cancer Research
News Oct 11, 2005
The grant comes under the NIH’s Center of Biomedical Research Excellence (COBRE) program and is one of the largest research awards to Brown in recent years.
Brown received its first five-year, $11-million COBRE award in 2000. That grant served as a springboard for the creation of the Center for Genomics and Proteomics.
“The COBRE awards are playing a vital role in expanding Brown’s research portfolio and fueling the growth of the Division of Biology and Medicine and its Medical School,” said Eli Y. Adashi, M.D., dean of medicine and biological sciences.
“They’ve created advanced biomedical facilities and well-trained scientists that will be recruited for a cause of great consequence – the fight against cancer.”
John Sedivy, director of the Center for Genomics and Proteomics and chair of the Department of Molecular Biology, Cell Biology and Biochemistry and project’s principal investigator, said that renewed COBRE funding will support research that explores how cancer cells develop from normal cells.
Five faculty members will study topics such as DNA damage, cell growth and division, and hormone signaling – all of which can contribute to the development or spread of cancer.
“Cancer cells are rogues: they don’t obey outside signals,” Sedivy said. “So if we had a better understanding of what is happening inside these cells, we could design more effective prevention measures or treatment methods. There is great importance in this basic research.”
The new COBRE award will mainly fund research projects, while the first mostly paid for equipment and facilities.
These included Rhode Island’s first transgenic facility, where mice with altered DNA are bred for scientists at Brown and its affiliated hospitals.
In addition, powerful microscopes were purchased along with sophisticated instruments to study gene activity and protein structure.
These tools are used not only to study cancer, but also fertility, aging and brain development as well as heart disease, diabetes and addiction.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.